Search PubMed⌕ Search

Biomedical subjects

E Teske

Publications and source records attributed to E Teske.

At least 37 records · Page 2Linked to original sources
PubMed2002

Prognostic significance of a new histologic grading system for canine osteosarcoma.

Histologic grade is an important determinant in clinical outcome of human osteosarcoma (OS). In this study, the histologic characteristics of primary and metastatic canine OS were evaluated using a new classification system. Histologic characteristics were classified in 166 primary and 34 metastatic canine OS. Prognostic variables for clinical outcome were determined using multivariate analysis. Most OS were histologically characterized by severe to extreme cellular pleomorphism, a variable number of mitoses, small to moderate amounts of matrix, a high percentage of tumor cells, and minimal to moderate amounts of necrosis. Tumor invasion into vessels was present in 117/152 (71%) tumors, and 12/50 (24%) of the regional lymph nodes had evidence of metastasis. Classification of the 166 tumors resulted in seven (4%) grade 1, 34 (21%) grade II, and 125 (75%) grade III OS. In the multivariate analysis, histologic grade III OS and elevated pretreatment plasma alkaline phosphatase (AP) levels were independent predictors of clinical outcome. Dogs with high-grade tumors and elevated AP should be carefully evaluated for the presence of metastatic disease before starting adjunctive therapy protocols.

Animals↗
PubMed2001

[Malignant lymphoma in the horse: an atypical clinical manifestation].

In this case report we describe an atypical clinical manifestation of malignant lymphoma in a horse. The most obvious clinical symptoms were hyperaemic mucosae and skin lesions. The skin and mucosal lesions appeared to be caused by a leukemic form of malignant lymphoma. The lymphocytosis consisted mainly of different populations of T-lymphocytes. Histopathology and immunohistochemistry identified the malignant lymphoma as a T-cell rich B-cell lymphoma.

Animals↗
PubMed2001

[The reliability of vaginal cytology in determining the optimal mating time in the bitch].

The reliability of vaginal cytology for determining the optimal mating period is controversial. The importance of the site for obtaining the smear (the vestibule or the vagina) and the best staining method are also unclear. Therefore, we investigated the reliability of vaginal cytology as compared to plasma progesterone concentrations for determining the optimal mating period. Additionally, the influence of different locations for obtaining the smears and of the staining methods, i.e. May-Grünwald-Giemsa or Papanicolaou, a method that stains keratin in superficial cells, was examined. In total, the vaginal cytology of 35 bitches during the follicular phase was examined three times a week, until the optimal time for mating was established, based on plasma progesterone concentrations measured with a 125Iodine radio-immunoassay. The results indicate that vaginal cytology is not useful for determining the optimal mating period in bitches, since mating according to cytological findings would have resulted in only 28% of the bitches being mated at the proper time. The site for obtaining the smear and the staining method did not affect accuracy. It is therefore concluded that cytology is not useful in breeding management to determine the optimal mating period. It can be used, however, to determine the stage of the cycle in general, e.g. the early part of the follicular phase or the metoestrus and the detection of disorders in the follicular phase. For this purpose, a smear from the vestibule, stained with a morphological staining method, provides sufficient information.

Animals↗
PubMed2001

Assessment of cytological criteria for diagnosing basal cell tumours in the dog and cat.

A retrospective study was undertaken in which cytological features of basal cell tumours from 18 dogs and 12 cats were examined. Fine-needle aspiration biopsy was performed for cytological examination and diagnosis was confirmed on histopathological examination of excised tumour specimens. Cytological smears were analysed for occurrence of cystic areas, as well as frequencies of squamous cells, fibrocytes, fibroblasts, neutrophils, lymphocytes, mast cells, melanocytes and basal cells. Basal cell aggregates were examined for indicators of malignancy, evidence of basaloid cell structure, well defined cellular borders and cell aggregation patterns. Cellularity and quality of smears was moderate to good, although, in six aspirates, cellularity was poor due to a high amount of degenerate material within the tumours. Fifteen of the smears revealed between one and three nuclear criteria of malignancy. However, despite the less well differentiated appearance of basal cells that was sometimes seen, the tumours were considered benign based on histopathological examination. Basal cell tumours are therefore likely to be underdiagnosed on cytological examination due to non-specific features. The occurrence of other cell populations and lack of cells with basaloid structures and linear aggregation patterns might further confuse the tumour diagnosis. The authors conclude that the cytological diagnosis of basal cell tumours can be based on the criteria described in the present study.

Animals↗
PubMed2001

[Clinical experiences with cytology in the dog].

In a retrospective study (1995) cytological diagnoses of 3987 specimen of different origin in the dog were evaluated. Biopsies were performed at the Department of Clinical Sciences of Companion animals at the University of Utrecht or sent in by external practitioners. Biopsies were obtained from different regions including skin/subcutis, mammary gland, lymph node, external ear canal, kidney, urinary bladder, urethra, prostatic gland, testes, bone, bone marrow, synovia, nose, oral cavity, cerebrospinal fluid, bronchial lavage, lung, spleen, liver, conjunctiva, and retrobulbar region. The majority of biopsies were obtained from skin/subcutis (n = 1815), lymph node (n = 706), and mammary gland (n = 415). A high percentage of non-diagnostic biopsies were observed with biopsies of lung, mammary gland, cerebrospinal fluid, external ear canal, and oral cavity. The frequencies of diagnoses in the different areas will be presented and the diagnostic indications of cytology are discussed.

Animals↗
PubMed1999

[The hematologic analyzer Vet ABC: evaluation of its use for dogs and cats].

The blood analyser Vet ABC was evaluated using the blood of dogs and cats. The correlation of results with those obtained with standard reference methods, reproducibility, and ease of operation were investigated. Good accuracy reproducibility were found in both species for leucocyte and erythrocyte counts, haematocrit, haemoglobin level, MCV, MCH, and MCHC. However, for some parameters new reference values will have to be established. The Vet ABC is not reliable for the measurement of platelets in the cat, and in the dog it does not give reproducible measurements of low numbers of platelets. In general, the Vet ABC is easy to use and does not need much maintenance.

Animals↗
PubMed1999

[Risks of using cytostatic drugs in veterinary medical practice].

Little is known about the chronic health problems caused by working with cytotoxic drugs. These drugs, including mitotane (Lysodren), chlorambucil (Leukeran), and azathioprine (Imuran), are usually teratogenic but can also be mutagenic and carcinogenic. The principle governing working with cytotoxics is to keep exposure as low as possible (the ALARA principle, as low as reasonably achievable). The Dutch Arbo-wet (Factories Act) requires that employer and employee restrict exposure to a minimum. This necessitates relatively expensive facilities, trained personnel, and good procedures. The owners and other people close to the patient are also potentially at risk and should be told of this and informed about drug administration and the disposal of faeces, vomit, urine, saliva, and blood. The prescription and/or administration of cytotoxic drugs, including those that are used as immunosuppressive agents in veterinary medicine, should be restricted to specialist veterinarians who have adequate knowledge and appropriate facilities to work with these agents. A work group to establish standards for working with cytotoxic drugs in veterinary practice is advocated.

Abnormalities, Drug-Induced↗
PubMed1999

Results of non-selective adrenocorticolysis by o,p'-DDD in 129 dogs with pituitary-dependent hyperadrenocorticism.

One hundred and twenty-nine dogs with pituitary-dependent hyperadrenocorticism were treated according to a protocol aimed at the complete destruction of the adrenal cortices by the administration of o,p'-DDD (mitotane) at a daily dose of 50 to 75 mg/kg bodyweight for 25 days. On the third day, glucocorticoid and mineralocorticoid supplementation was begun for the induced adrenocortical insufficiency. The first followup examination after completion of the 25-day course and the subsequent twice-yearly follow-up examinations included physical examination and measurements of plasma concentrations of sodium and potassium to optimise substitution therapy. In 19 dogs the full course of 25 days treatment could not be completed. Of the 110 dogs which received the full course of treatment, the administration had to be stopped temporarily in 32 because of side-effects, such as anorexia and vomiting. The actual dose of o,p'-DDD administered was not significantly different in the dogs with and without these side-effects. Clinical remission occurred in 111 dogs (86 per cent), of which 43 (39 per cent) had a relapse. The estimated one-year disease-free fraction was 77 per cent (95 per cent confidence interval [CI]: 67 to 85 per cent). The estimated one-year survival fraction was 80 per cent (95 per cent CI: 71 to 87 per cent), the two-year survival was 69 per cent (95 per cent CI: 59 to 78 per cent), and the three-year survival was 61 per cent (95 per cent CI: 49 to 71 per cent). The bodyweight and age of the dog, and vomiting occurring during the period of treatment, were positively correlated with the length of the disease-free period, whereas weakness during the treatment and resistance to dexamethasone suppression of the urinary corticoid/creatinine ratios at the start of the treatment were associated with a relatively short survival time.

Adrenal Glands↗
PubMed1999

Diagnostic value of a microsatellite DNA marker for copper toxicosis in West-European Bedlington terriers and incidence of the disease.

Recently, linkage of a DNA microsatellite marker to inherited copper toxicosis has been reported in American Bedlington terrier families. Due to the fact that there is little exchange of breeding stock between the USA and Europe, it remains to be investigated whether in Europe the marker is informative and is linked with the disease. We have therefore examined the diagnostic value of the microsatellite marker in the European Bedlington. In 130 dogs at least one year of age (62 from The Netherlands, 35 from Belgium, and 33 from Germany) histo- or cytochemical staining of copper was done in liver biopsies. Based on liver histo- or cytochemistry, 51 dogs were obligate carriers, and 25 dogs had copper toxicosis. The inferred genotypes of these 76 dogs were compared with the marker genotypes. All dogs with the disease were homozygous for the 167 bp marker allele. All obligate carriers were heterozygotes with the 167 bp and a 163-bp alleles. All phenotypically healthy dogs were either homozygous for the 163 bp allele or heterozygous. Thus, the marker was in complete linkage disequilibrium with the putative copper toxicosis gene with the 167 bp allele in phase with the disease allele. The frequencies of the 167 bp and the 163 bp allele, respectively, were 0.33 and 0.67 in Dutch dogs, 0.31 and 0.69 in German dogs, and 0.57 and 0.43 in Belgian dogs. We have confirmed the utility of this marker for diagnosis of inherited copper toxicosis in European Bedlington terriers.

Animals↗
PubMed1999

Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma.

The results of an L-asparaginase-based continuous chemotherapy protocol (n = 52) versus a short doxorubicin-based induction chemotherapy protocol (n = 65) were evaluated in 117 dogs with malignant lymphoma. There were no differences between the two groups in patient characteristics or incidence of protocol-related toxicity. Complete remission was induced in 71.2% of the dogs treated with the L-asparaginase protocol and in 67.7% of the dogs treated with the doxorubicin-plus protocol. The calculated Kaplan-Meier one- and two-year survival fractions in the L-asparaginase group were 48% and 26%, and in the doxorubicin-plus group 35%, and 22%, respectively. Differences in remission and survival between the two treatment groups were not significant. A multivariate Cox proportional hazards survival analysis revealed that elevated pretreatment plasma creatinine concentration and prior treatment with prednisolone were associated with shorter survival times. An elevated pretreatment plasma creatinine concentration and total leucocyte count were associated with a decrease in the disease-free period. Differences in efficacy and toxicity between the two protocols were not significant. There is no apparent advantage in using the continuous L-asparaginase protocol, and the shorter doxorubicin-plus protocol is less expensive and less time consuming.

Animals↗
PubMed1999

Prognostic factors for treated canine malignant lymphoma.

The aim of this study was to investigate the prognostic importance of different clinical, immunohistologic and tumor proliferation characteristics in dogs with malignant lymphoma treated with chemotherapy. From 74 dogs with malignant lymphoma at least one enlarged peripheral lymph node was taken for biopsy before chemotherapy following a standardized protocol (vincristine, cyclophosphamide, prednisolone, doxorubicin, and L-asparaginase). The variables evaluated as prognostic factors were age, sex, and tumor stage, as well as histomorphologic grade (Kiel classification, Working Formulation), immunophenotype (using markers for CD3 and CD79a), and cell proliferation (Ki-67, proliferation cell nuclear antigen, mitotic index, and argyrophil nucleolar organizer regions [AgNORs]) in extirpated lymph nodes. All markers were used on routinely formalin-fixed, paraffin-embedded tissues. The AgNORs were assessed qualitatively, based on the AgNOR pattern distribution, and quantitatively using image analysis and routine counting. In both univariate and multivariate survival analyses, AgNORs were a valuable prognostic marker for the treatment of canine malignant lymphomas. Based on the results of the multivariate analysis longer survival time correlated with a B-cell type, a larger mean AgNOR area, a larger total AgNOR area, a shorter distance between two AgNORs, and a smaller AgNOR area to nucleus ratio. Longer disease-free survival time correlated with a smaller number of AgNORs per nucleus, a larger mean AgNOR area, a larger maximal AgNOR area, and a larger total AgNOR area. This study clearly demonstrates the additional benefit of the use of AgNORs in predicting treatment outcome in dogs with malignant lymphoma.

Analysis of Variance↗
PubMed1998

Multi-agent chemotherapy for mast cell tumours in the dog.

Seventeen dogs with mast cell tumours received chemotherapy. Fifteen dogs were treated with a vincristine, cyclophosphamide, hydroxyurea, and prednisolone (VCHP) regimen. Seven of these were later switched to doxyrubicin and prednisolone either because they stopped responding or because they did not respond from the start of the treatment. Two dogs received the latter regimen as the primary therapy. All dogs were treated with cimitidine and metoclopramide to minimize the effect of paraneoplastic syndrome associated with histamine release. Ten of the 17 dogs were found to respond (4/17 complete response (CR), 6/17 partial response (PR)). Response duration varied from 39 to 910 days (median 53 days), including 3 dogs with a CR that lasted more than 2 years. Survival time in responders varied from 41 to 910 days (median 97 days) and from 30 to 126 (median 39) in the other 7 dogs. Dogs that became refractory to VCHP did not respond to doxyrubicin and prednisolone. It is concluded that multi-agent chemotherapy has anti-tumour activity in a considerable proportion of dogs with mast cell tumours, but its efficacy is variable. The multivariate analyses showed that significant factors predicting survival in dogs with mast cell tumours were sex (P = 0.009), absence or presence of non-abdominal distant metastases, or abdominal metastases, respectively (P = 0.023), and malignancy grade of the tumours (P = 0.053).

Animals↗
PubMed1997

The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial.

The efficacy of i.v. versus s.c. administration of Glucantime (100 mg/kg of body weight/day) was studied in 41 dogs with leishmaniasis without serious renal insufficiency. Remission was obtained in 35 dogs (85.4%) after 3 to 6 weeks of treatment but there was a relapse within 1 year in 26 dogs (74.3%). The median period of remission was 6 months. Cross-over therapy resulted in remission in 17 of 20 dogs. The percentage of remission after initial and cross-over therapy, the median relapse free period, and survival did not differ significantly between the two groups. There were very few complications and most were of minor clinical importance. Thrombophlebitis developed in one dog after i.v. injection. In dogs with leishmaniasis without serious renal insufficiency, there is a 75% probability of survival for more than 4 years following treatment with Glucantime for 3 to 6 weeks, with additional treatment when relapses occur.

Animals↗